NCT05414331 (DROP-BB) is a NA clinical trial of Discontinuing all beta-blocker in Coronary Artery Bypass, sponsored by Yale University.

Who is sponsoring NCT05414331?

NCT05414331 is sponsored by Yale University.

What drugs are being tested in NCT05414331?

Interventions in NCT05414331: Discontinuing all beta-blocker.

What condition does NCT05414331 study?

NCT05414331 studies Coronary Artery Bypass.

Is NCT05414331 still recruiting?

NCT05414331 is currently terminated. Last updated 6 April 2025.

Last reviewed 2025-04-06 · How we verify

NCT05414331: DROP-BB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

WithDRawal Impact Of Postoperative Beta-Blocker

Terminated NA Last updated 6 April 2025

What this trial tests

NA trial testing Discontinuing all beta-blocker in Coronary Artery Bypass in 43 participants. Terminated before completion.

Timeline

4 November 2022

Primary endpoint
2 May 2024

30 May 2024

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	43
Start date	4 November 2022
Primary completion	2 May 2024
Estimated completion	30 May 2024
Sites	1 location across United States

Drugs / interventions tested

Discontinuing all beta-blocker

Conditions studied

Coronary Artery Bypass — all drugs for Coronary Artery Bypass →

Sponsor

Yale University

Who can join

18 and older, any sex, with Coronary Artery Bypass. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will evaluate the impact of withdrawing beta-blocker medication after coronary artery bypass surgery with this randomized controlled trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Bypass

Currently open trials in the same condition.

NCT07390903 — GLS in Difficult CPB Weaning · recruiting
NCT07528482 — Effects of Reflexology and Cold Application Before Chest Tube Removal in CABG Patients · NA · recruiting
NCT07035171 — CABGpreHAB - a Feasibility Study Protocol · NA · recruiting
NCT06977230 — Remote Ischemic Preconditioning in Type 2 Diabetic Patients Undergoing CABG · NA · recruiting
NCT06602336 — A Single Centre Study Comparing Continuous Interstitial Fluid Lactate Detection to Standard Measurements of Lactate in P · NA · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05414331 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 6 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05414331.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing